MoonLake Immunotherapeutics (MLTX) Cash & Current Investments (2020 - 2026)

MoonLake Immunotherapeutics' Cash & Current Investments history runs 7 years deep, the most recent figure standing at $357.9 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 25.45% year-over-year to $357.9 million in Q1 2026; TTM through Mar 2026 was $357.9 million, a 25.45% decrease from a year earlier, with the FY2025 full-year figure at $394.0 million, down 12.07% from the prior year.
• Cash & Current Investments fell to $357.9 million in Q1 2026 per MLTX's latest filing, from $394.0 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $547.1 million in Q1 2024 and bottomed at $63.0 million in Q1 2023.
• The 5-year median for Cash & Current Investments is $436.6 million (2024), against an average of $367.2 million.
• Across the five-year window, Cash & Current Investments soared 8533.99% in 2022 and sank 37.61% in 2023, its largest moves.
• Year by year, Cash & Current Investments stood at $72.1 million in 2022, then jumped by 608.6% to $511.0 million in 2023, then dropped by 12.32% to $448.0 million in 2024, then decreased by 12.07% to $394.0 million in 2025, then retreated by 9.15% to $357.9 million in 2026.
• Per Business Quant, the three latest MLTX Cash & Current Investments figures stand at $357.9 million (Q1 2026), $394.0 million (Q4 2025), and $380.5 million (Q3 2025).